Bladder Cancer VL

Consensus Statement on Flexible Blue Light Cystoscopy (BLC™) with Cysview® - Yair Lotan

Yair Lotan discusses the recently published consensus statement on flexible blue light cystoscopy (BLC™) with Cysview ® . His presentation is centered around the published consensus in Nature Reviews developed by multiple experts (authors) in bladder cancer. Yair discusses the role of blue light flexible cystoscopy with CYSVIEW in non-muscle invasive bladder cancer. The expert consensus group met...

Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy - Sia Daneshmand

Sia Daneshmand discusses a study published in European Urology which aimed to look at all the atypical cytologies to evaluate the performance of Cxbladder diagnostic tests to either rule out low-risk individuals or identify patients at a high risk of urothelial carcinoma. Cxbladder diagnostic tests combine genomic information from urinary mRNA with phenotypic information. Biography: Siamak (Sia) D...

Comparative Analyses of Costs and Survival Between Radical Cystectomy and Trimodal Therapy - Stephen Williams

Ashish Kamat invites Stephen Williams to present on costs and survival analysis between radical cystectomy and trimodal therapy. He shares results of two studies which patients from 2002-2011 were looked at in both studies focusing on methodology/statistical analyses and the outline of outcomes. This work found that trimodal therapy had significantly worse survival, these findings persisted across...

Blue Light Cystoscopy (BLC™): What Urologist Want to Know - Anne Schuckman

Anne Schuckman, MD presents the information that supports her decision to use blue light cystoscopy with CYSVIEW in the clinic. She takes us through the data of the studies and her experiences too. Biography: Anne Kathryn Schuckman, MD, Assistant Professor of Clinical Urology, Keck School of Medicine, USC, Dr. Anne Schuckman graduated from Stanford University and completed her medical training at...

BCG Shortage An Update - Jonathan Rubenstein

Neal Shore and colleague, Jonathan Rubenstein provide an update on the advances and developments that have been communicated in regards to the truly important challenge of BCG shortage for the use of patients with a high-risk non-muscle invasive bladder cancer. This is an international problem. In a previous program Neal Shore, Ashish Kamat, and Jonathan Rubenstein talked about alternative dosing...

The Role of the Surgeon in the Treatment of Bladder Cancer- Jens Bedke

Jens Bedke, MD discusses the multimodal approach for the treatment of bladder cancer from the surgeon's perspective. While cystectomy offers the greatest benefit to most patients, Dr. Bedke emphasizes the importance of differentiating patients, tumor types and tumor grades to guide patient care. Along with the role of neoadjuvant chemotherapy, Dr. Bedke discusses treatment approaches for the varia...

Immunotherapy in the Peri-Operative Setting for Bladder Cancer - Thomas Powles

Thomas Powles, MD, and Charles Ryan, MD share in a discussion regarding the use of immunotherapy in the peri-operative setting for bladder cancer and the current state of immunotherapy for bladder cancer. Dr. Powles, while excited about the evolving role of immunotherapy, is less enthusiastic on the use of combination immune therapy based on recent findings. Monotherapy with either atezolizumab (A...

What is New on Bladder Cancer Treatment: ASCO GU 2019? - Josh Meeks

Josh Meeks discusses the bladder cancer data from the ASCO GU 2019 meeting that is compelling from the perspective of urologists in this conversation with Alicia Morgans. Biographies: Josh J. Meeks, MD, PhD, Assistant Professor of Urology and Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine, Chicago Illinois Alicia Morgans, MD, MPH , Associate Professor of...

ERAS in Bladder Cancer - Sia Daneshmand

Sia Daneshmand discusses the history of fast-tracked and streamlined post-operative cystectomy care for patients and associated improved outcomes in his conversation with Ashish Kamat. He details the development of the ERAS protocol and the significant milestones that have been realized in this journey to improved patient outcomes after cystectomy. Biographies: Siamak Daneshmand, MD Dr. Sia Danesh...

The State of Immunotherapy in Bladder Cancer - Thomas Powles

Thomas Powles discusses the current state of immunotherapy in the treatment of muscle invasive bladder cancer (MIBC) specifically in second line after cisplatin-based chemotherapy with Chuck Ryan. He discusses the recent learnings that immunotherapy offers long-term durable response in 10 - 20% of the cisplatin-eligible patient population who are biomarker positive. They discuss ongoing clinical t...

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.